Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Seeks UK MHRA Marketing Approval for Chronocort to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine","pharmaFlowCategory":"D","amount":"$13.2 million","upfrontCash":"$0.5 million","newsHeadline":"Citrine Medicine Announces Strategic Partnership with Diurnal To Bring Alkindi\u00ae To China For Use In Pediatric Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Chronocort\u00ae Phase 3 and Safety Extension Study Results Published in JCEM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"$1.0 million","newsHeadline":"Diurnal Triggers $1.25m in Milestone Payments from Citrine Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Diurnal receives European Commission approval for Efmody\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group launches Efmody in UK to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody\u00ae in Switzerland","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Diurnal Group

    Menu

    Diurnal Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland

              Details:

              Efmody® is a modified-release preparation of hydrocortisone that has been specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Efmody

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: EffRx Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Diurnal Group launches Efmody in UK to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia

              Details:

              Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, a rare condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Efmody

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Diurnal Triggers $1.25m in Milestone Payments from Citrine Medicine

              Details:

              The $1.25 million milestone payment has been triggered as a result of the recent European Commission’s approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for Alkindi.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Efmody

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Citrine Medicine

              Deal Size: $2.2 million Upfront Cash: $1.0 million

              Deal Type: Partnership June 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Diurnal Group plc - Diurnal receives European Commission approval for Efmody®

              Details:

              Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Efmody

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Diurnal Group plc - Chronocort® Phase 3 and Safety Extension Study Results Published in JCEM

              Details:

              The Phase 3 study results published by the JCEM found that although the standard-deviation-score-focused primary endpoint of the study was missed, Chronocort® improved morning and early afternoon biochemical control for adults with CAH over standard glucocorticoid therapy.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Chronocort

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Citrine Medicine Announces Strategic Partnership with Diurnal To Bring Alkindi® To China For Use In Pediatric Congenital Adrenal Hyperplasia

              Details:

              Citrine will be responsible for obtaining registration for Alkindi® as a treatment for paediatric patients in China and for all commercialisation activities, including pricing and reimbursement.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Alkindi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Citrine

              Deal Size: $13.2 million Upfront Cash: $0.5 million

              Deal Type: Licensing Agreement January 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

              Details:

              Eton Pharmaceuticals Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eton Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Diurnal Seeks UK MHRA Marketing Approval for Chronocort to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia

              Details:

              The submission for the MHRA is based on the data from the Company’s Phase 3 study, an open-label safety extension study of Chronocort® and written formal Scientific Advice received in April 2019 confirming the clinical and regulatory pathway for Chronocort® for CAH treatment.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Genetic Disease Product Name: Chronocort

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi®

              Details:

              Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: EffRx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Diurnal Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

              Details:

              The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eton Pharmaceuticals

              Deal Size: $7.5 million Upfront Cash: $3.5 million

              Deal Type: Licensing Agreement March 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY